Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-04-29 | Daniel B. Soland, age 62, has served as a director of our company since March 2015... The following table shows, for the fiscal year ended December 31, 2019, certain information with respect to the compensation of all non-employee directors of the Company during 2019... Daniel B. Soland: Fees Earned or Paid in Cash $70,000, Option Awards $322,439, Total $392,439. |
| 2021-04-30 | Daniel Soland 63 Director ... "Fees Earned or Paid in Cash" represents an annual retainer as a Board member of $50,000, an additional retainer as an Audit Committee member (non-chair) of $10,000 and an additional retainer as NCG Committee chair of $10,000. "Option Awards" includes the fair value of 5,579 stock options granted June 23, 2020 with an exercise price of $52.73. "Stock Awards" includes the fair value of 3,059 restricted stock units granted June 23, 2020.As of December 31, 2020, an aggregate of 128,079 stock options and 3,059 restricted stock units that had been granted to Mr. Soland were outstanding. |
| 2022-04-29 | Daniel Soland 63 Director... The following table shows, for the fiscal year ended December 31, 2021, certain information with respect to the compensation of all non-employee directors of the Company during 2021... Daniel Soland Fees Earned or Paid in Cash $70,000, Option Awards $167,690, Stock Awards $159,008, Total $396,698. |
| 2023-05-01 | Daniel B. Soland has served as a director of the Company since March 2015. Mr. Soland is currently Senior Vice President and Chief Operating Officer of Idera Pharmaceuticals, Inc., and served as Chief Executive Officer of uniQure N.V., a human gene therapy company, from December 2015 until September 2016. Mr. Soland previously served as Senior Vice President and Chief Operating Officer of ViroPharma, Inc. starting in 2008 until it was acquired in 2014, and as Vice President and Chief Commercial Officer of ViroPharma from 2006 to 2008. During his tenure at ViroPharma, Mr. Soland managed the commercial, manufacturing and quality organizations, helped build the company’s commercial infrastructure in the United States, Europe, and Canada and led the launch of Cinryze®, one of the most successful ultra-orphan drugs in the United States. Mr. Soland served as President, Chiron Vaccines, of Chiron Corporation from 2005 to 2006 and led the growth of the vaccine business to over $1 billion in sales. From 2002 through 2005, Mr. Soland served as President and Chief Executive Officer of Epigenesis Pharmaceuticals. Earlier in his career, Mr. Soland worked for GlaxoSmithKline in increasing roles of responsibility from 1993 to 2002, including as Vice President and Director, Worldwide Marketing Operations, GSK Biologicals. He currently serves on the boards of directors of DBV Technologies S.A. and KalVista Pharmaceuticals, Inc. Mr. Soland holds a B.S. in pharmacy from the University of Iowa. The NCG Committee believes that Mr. Soland is qualified to serve as a member of our board of directors based on his extensive management and commercial expertise in the biopharma industry. The following table shows, for the fiscal year ended December 31, 2022, certain information with respect to the compensation of all non-employee directors of the Company during 2022. Mr. Davis, our Chief Executive Officer, does not receive additional compensation for his services as a director. Daniel Soland Fees Earned or Paid in Cash $70,000 Option Awards $156,098 Stock Awards $156,245 All Other Compensation $0 Total $382,343 |
| 2024-04-26 | Daniel B. Soland has served as a director of the Company since March 2015. Mr. Soland most recently served as Senior Vice President and Chief Operating Officer of Idera Pharmaceuticals, Inc. from January 2021 to January 2023, and previously served as Chief Executive Officer of uniQure N.V., a human gene therapy company, from December 2015 until September 2016. Mr. Soland previously served as Senior Vice President and Chief Operating Officer of ViroPharma, Inc. starting in 2008 until it was acquired in 2014, and as Vice President and Chief Commercial Officer of ViroPharma from 2006 to 2008. During his tenure at ViroPharma, Mr. Soland managed the commercial, manufacturing and quality organizations, helped build the company’s commercial infrastructure in the United States, Europe, and Canada and led the launch of Cinryze®, one of the most successful ultra-orphan drugs in the United States. Mr. Soland served as President, Chiron Vaccines, of Chiron Corporation from 2005 to 2006 and led the growth of the vaccine business to over $1 billion in sales. From 2002 through 2005, Mr. Soland served as President and Chief Executive Officer of Epigenesis Pharmaceuticals. Earlier in his career, Mr. Soland worked for GlaxoSmithKline in increasing roles of responsibility from 1993 to 2002, including as Vice President and Director, Worldwide Marketing Operation, GSK Biologicals. He currently serves on the board of directors of DBV Technologies S.A. During the past five years, Mr. Soland served on the board of directors of KalVista Pharmaceuticals, Inc. Mr. Soland holds a B.S. in pharmacy from the University of Iowa. The NCG Committee believes that Mr. Soland is qualified to serve as a member of our board of directors based on his extensive management and commercial expertise in the biopharma industry. The Board has an Audit Committee, a Compensation Committee, a Nominating and Corporate Governance Committee and a Scientific Advisory Committee. The following table provides membership and meeting information for 2023: Daniel B. Soland: Audit Committee, Nominating and Corporate Governance Committee (Chair). The following table shows, for the fiscal year ended December 31, 2023, certain information with respect to the compensation of all non-employee directors of the Company during 2023. Daniel B. Soland: Fees Earned or Paid in Cash $70,000, Option Awards $158,770, Stock Awards $158,983, Total $387,752. |
| Filing Date | Source Excerpt |
|---|---|
| 2019-08-23 | Mr. Soland holds a B.S. in Pharmacy from the University of Iowa. We believe Mr. Soland is qualified to serve on our Board because of his extensive executive and management experience in the pharmaceutical industry worldwide. |
| 2020-08-25 | Mr. Soland holds a B.S. in Pharmacy from the University of Iowa. We believe Mr. Soland is qualified to serve on our Board because of his extensive executive and management experience in the pharmaceutical industry worldwide. |
| 2021-08-17 | Mr. Soland holds a B.S. in Pharmacy from the University of Iowa. His qualifications are based on executive and management experience in the pharmaceutical industry. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-04-26